Not Signed In -
Cholesterol |
|
|
Clinical Trial: A 12 Week Study to Assess the Effectiveness of an Investigational Cholesterol-Lowering Drug in Patients That Have Been Hospitalized for a Possible Heart Problem
This study is currently recruiting patients.
Verified by Merck July 2005
|
Purpose
Investigate the effect of an investigational cholesterol-lowering drug in patients who are currently taking an approved medication for hypercholesterolemia (high cholesterol levels) and have been hospitalized for a heart problem.
(INTERNATIONAL STUDY LOCATIONS ONLY)
| Condition | Intervention | Phase |
|---|---|---|
| Hypercholesterolemia | Drug: MK0653A, ezetimibe (+) simvastatin | Phase IV |
MedlinePlus related topics: Cholesterol
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- Patients greater than 18 years old, who were admitted to a hospital for an investigation of a heart problem and currently receiving an approved medication to lower cholesterol
Exclusion Criteria:
- Patients who have congestive heart failure (CHF), uncontrolled high blood pressure, poorly controlled blood sugar, impaired kidney function, or HIV.
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00132717
Australia
Merck Sharp & Dohme (Australia) Pty Ltd., South Granville, NSW 2142, Australia; Recruiting
Linda Swan, MD 612-9795-9377
Austria
Merck Sharp & Dohme Gmbh, Vienna, 1220, Austria; Recruiting
Andras Madai, MD 43.1.26.044.182
Belgium
Merck Sharp & Dohme B.V., BRUXELLES, 1180, Belgium; Recruiting
Dirk Poelaert, MD 32-2-373-4310
Chile
Merck Sharp & Dohme (I.A.) Corp., Santiago, 6761641, Chile; Recruiting
Margarita Charlin, MD 562-655-8850
Croatia
Merck Sharp & Dohme IDEA, Inc., Zagreb, 10 010, Croatia; Recruiting
Goranka Glad Scherr, MD 385 1 66 44 336
France
Laboratoires Merck Sharp & Dohme - Chibret, Paris Cedex 8, 75114, France; Recruiting
Jean-Marie Goehrs, MD (33.1) 47.54.89.90
Germany
Msd Sharp & Dohme Gmbh, Haar, 85540, Germany; Recruiting
Ottfried Zierenberg, PhD 49 89 4561 1102
Hong Kong, Hong Kong Island
Merck Sharp & Dohme (Asia) Ltd., Causeway Bay, Hong Kong Island, Hong Kong; Recruiting
Linda Semlitz (Gilbert), MD 852 2835-9860
Italy
Merck Sharp & Dohme (Italia) S.P.A., Roma, 191, Italy; Recruiting
Gianfranco Botta, MD +39 06 36 191 187
Malaysia
Merck Sharp & Dohme (I.A.) Corp, Selangor, 46300, Malaysia; Recruiting
Nazrin Azli, MD 603-79662848
Singapore
Merck Sharp & Dohme (Singapore), Singapore, 199555, Singapore; Recruiting
Justin Chin, MD +65 6393 7683
Switzerland
Merck Sharp & Dohme - Chibret, A.G., Glattbrugg, 8152, Switzerland; Recruiting
Martin Fenner, MD 0041-1-828 7308
United Kingdom, Hertfordshire
Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire, EN11 9BU, United Kingdom; Recruiting
John Young, MD 44 1992 452341
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2004_046
Last Updated: August 19, 2005
Record first received: August 2, 2005
ClinicalTrials.gov Identifier: NCT00132717
Health Authority: France: Afssaps - French Health Products Safety Agency
ClinicalTrials.gov processed this record on 2005-08-23
Last Updated: August 19, 2005
Record first received: August 2, 2005
ClinicalTrials.gov Identifier: NCT00132717
Health Authority: France: Afssaps - French Health Products Safety Agency
ClinicalTrials.gov processed this record on 2005-08-23
email this page
print this page
bookmark this page
feedback on this page
